CTOs on the Move

Arvinas

www.arvinas.com

 
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.arvinas.com
  • 5 Science Park 395 Winchester Avenue
    New Haven, CT USA 06511
  • Phone: 203.535.1456

Executives

Name Title Contact Details
Justin Scheidegger
 Director, IT Operations, Infrastructure and Security Profile

Funding

Arvinas raised $41M on 10/21/2015
Arvinas raised $55M on 04/04/2018

Similar Companies

480 Biomedical

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

VisionGate

VisionGate, Inc., is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.